Table 2:
Comparison of propensity score–matched patients who underwent resection for gastric adenocarcinoma following neoadjuvant therapy (n=130).a
| CT (n=65) | CRT (n=65) | P Value | |
|---|---|---|---|
| Age, years | 62±12 | 61±13 | 0.843 |
| Male | 58.5% | 53.8% | 0.362 |
| Race | 0.751 | ||
| White | 50.8% | 60.0% | |
| Hispanic | 21.5% | 15.4% | |
| Black | 12.3% | 13.8% | |
| Other | 15.4% | 10.8% | |
| Histology | 0.362 | ||
| Well Differentiated | 1.5% | 0.0% | |
| Moderately Differentiated | 24.6% | 23.1% | |
| Poorly Differentiated | 70.8% | 76.9% | |
| Other | 3.1% | 0.0% | |
| Signet Ring Cells | 53.8% | 43.1% | 0.146 |
| Linitis Plastica | 6.3% | 1.6% | 0.187 |
| EUS T stage | 0.543 | ||
| cT1 | 3.0% | 1.5% | |
| cT2 | 13.8% | 7.7% | |
| cT3 | 73.8% | 72.3% | |
| cT4 | 6.2% | 13.9% | |
| cTx | 3.1% | 3.1% | |
| EUS N Stage | 0.762 | ||
| cN0 | 52.3% | 46.2% | |
| cN1 | 41.5% | 47.7% | |
| cN2 | 3.1% | 1.5% | |
| cN3 | 0.0% | 1.5% | |
| cNx | 3.1% | 3.1% | |
| Procedure Performed | 0.155 | ||
| Total Gastrectomy | 41.5% | 58.5% | |
| Subtotal/Distal Gastrectomy | 53.9% | 38.5% | |
| Proximal Gastrectomy | 4.6% | 3.1% | |
| Lymphadenectomy, 15 or more | 84.6% | 81.5% | 0.408 |
| Mean LN Removed | 32±20 | 25±12 | 0.011 |
| Median LOS, days | 11(9–14) | 11(10–17) | 0.665 |
| Complications | |||
| Wound | 18.5% | 16.9% | 0.501 |
| Intraabdominal Infection | 9.2% | 12.3% | 0.389 |
| Leak | 1.5% | 7.7% | 0.104 |
| Respiratory | 7.7% | 15.4% | 0.136 |
| Renal | 1.5% | 3.1% | 0.501 |
| Cardiac | 4.6% | 6.2% | 0.499 |
| Anemia | 6.2% | 4.6% | 0.501 |
| Other | 18.5% | 10.8% | 0.161 |
| ypT Stage | <0.001 | ||
| ypT0 | 1.5% | 27.7% | |
| ypT1 | 23.0% | 16.9% | |
| ypT2 | 10.8% | 23.1% | |
| ypT3 | 36.9% | 23.1% | |
| ypT4 | 26.2% | 9.2% | |
| ypN Stage | 0.039 | ||
| ypN0 | 42.2% | 66.2% | |
| ypN1 | 26.6% | 18.5% | |
| ypN2 | 17.2% | 9.2% | |
| ypN3 | 14.1% | 6.2% | |
| DFS | 0.067 | ||
| Median DFS, mo(95% CI) | 51(5–97) | 122(69–175) | |
| 5 year DFS | 49.2% | 70.1% | |
| OS | 0.209 | ||
| Median OS, mo(95% CI) | 71(24–118) | 122(69–175) | |
| 5 year OS | 52.4% | 69.2% | |
a
CT, neoadjuvant chemotherapy; CRT, neoadjuvant chemotherapy plus chemoradiotherapy; EUS, endoscopic ultrasound; IQR, interquartile range; DFS, disease-free survival; CI, confidence interval; OS, overall survival.